Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia

Conclusion Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation TKIs in patients with newly diagnosed Ph+ ALL. Micro-Abstract The complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia treated with front-line chemotherapy plus ponatinib versus earlier generation tyrosine kinase inhibitors were compared in a meta-analysis and meta-regression. The patients treated with front-line ponatinib versus earlier generation treatments were more likely to achieve a CMR and had greater rates of 3-year OS.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research